醫(yī)療特長(zhǎng)：
從事原發(fā)和轉(zhuǎn)移性骨腫瘤和軟組織腫瘤的精準(zhǔn)診斷,、外科手術(shù)及靶向免疫治療。擅長(zhǎng)（1）骨肉瘤,、軟骨肉瘤,、尤文肉瘤、滑膜肉瘤等腫瘤廣泛切除和假體重建,，在復(fù)雜四肢,、骨盆和脊柱腫瘤的精準(zhǔn)切除、3D打印假體重建,、兒童可延長(zhǎng)假體重建方面具有豐富經(jīng)驗(yàn),；（2）轉(zhuǎn)移性骨腫瘤，尤其是脊柱轉(zhuǎn)移癌的綜合外科治療,，包括微創(chuàng)治療,、整塊切除重建，創(chuàng)造無(wú)瘤生存條件,，提高患者生活質(zhì)量,。（3）骨巨細(xì)胞瘤的靶向藥物治療和外科手術(shù)治療。
研究方向：
青少年惡性骨腫瘤的精準(zhǔn)切除和可延長(zhǎng)假體重建,；脊柱轉(zhuǎn)移癌的綜合外科治療
主要教育和工作經(jīng)歷：
1997.09-2003.06 山東大學(xué)臨床醫(yī)學(xué)系 學(xué)士學(xué)位
2003.09-2008.12 中山大學(xué)附屬第一醫(yī)院骨腫瘤科 博士學(xué)位
2007.09-2008.09 美國(guó)MD Anderson癌癥中心 博士后
2009.7-2011.12 中山大學(xué)附屬第一醫(yī)院骨腫瘤科 住院醫(yī)生
2011.12-2013.12 中山大學(xué)附屬第一醫(yī)院骨腫瘤科 主治醫(yī)師
2013.12-2019.12 中山大學(xué)附屬第一醫(yī)院骨腫瘤科 副主任醫(yī)師
2020.01-至今 中山大學(xué)附屬第一醫(yī)院骨腫瘤科 主任醫(yī)師
社會(huì)兼職：
中國(guó)抗癌協(xié)會(huì)肉瘤專業(yè)委員會(huì) 委員
中國(guó)抗癌協(xié)會(huì)肉瘤專業(yè)委員會(huì)基礎(chǔ)研究學(xué)組 副組長(zhǎng)
中國(guó)抗癌協(xié)會(huì)肉瘤專業(yè)委員會(huì)化放療學(xué)組 委員
中國(guó)抗癌協(xié)會(huì)肉瘤專業(yè)委員會(huì)軟組織肉瘤學(xué)組 委員
中華醫(yī)學(xué)會(huì)骨科分會(huì)骨腫瘤學(xué)組四肢工作委員會(huì) 委員
中國(guó)醫(yī)藥教育協(xié)會(huì)骨與軟組織腫瘤專業(yè)委員會(huì) 委員
廣東省醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì) 委員
《中華關(guān)節(jié)外科雜志（電子版）》 特約審稿人
《實(shí)用醫(yī)學(xué)雜志》 特約審稿人
論著：
發(fā)表SCI收錄文章40余篇,，其中第一/共同第一/通訊發(fā)表16篇，單篇最高影響因子16.806,。
以第一/共同第一/通訊作者發(fā)表的SCI文章：
- Lu B, Zou C*（共一）, Yang M, He Y, He J, Zhang C, Chen S, Yu J, Liu KY, Cao Q, Zhao W.Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. Adv Sci (Weinh). 2021 Aug 25:e2101895. doi: 10.1002/advs.202101895.
- Wa Q, Zou C*（共一）, Lin Z, Huang S, Peng X, Yang C, Ren D, Xu D, Guo Y, Liao Z, Wang B, Hu H, Huang S, He P.Ectopic Expression of miR-532-3p Suppresses Bone Metastasis of Prostate Cancer Cells via Inactivating NF-κB Signaling. Mol Ther Oncolytics. 2020 Apr 7;17:267-277. doi: 10.1016/j.omto.2020.03.024. eCollection 2020 Jun 26
- Li X, Wang L, Wang L, Yu J, Lu G, Zhao W, Miao C, Zou C#（共同通訊）, Wu J#.Overcoming therapeutic failure in osteosarcoma via Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles. Biomater Sci. 2020 Oct 1. doi: 10.1039/d0bm01296c.
- Zhang J*, Liu W*, Zou C*（共一）, Zhao Z, Lai Y, Shi Z, Xie X, Huang G, Wang Y, Zhang X, Fan Z, Su Q, Yin J, Shen J.Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor. Clin Cancer Res. 2020 Jun 1;26(11):2681-2692.
- Zou C*, Zhao Z*, Lin T, Huang Y, Xie X, Yin J, Huang G, Wang B, Shen J.Long-term outcomes of limb salvage treatment with custom-made extendible endoprosthesis for bone sarcoma around the knee in children. J Orthop Surg Res. 2020 Jan 16;15(1):14. doi: 10.1186/s13018-019-1534-x.
- Lu B, He Y, He J, Wang L, Liu Z, Yang J, Gao Z, Lu G, Zou C, Zhao W.Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma. Mol Cancer Res. 2020 Jan;18(1):57-67. doi: 10.1158/1541-7786.MCR-19-0470. Epub 2019 Oct 15.
- Wa Q, Huang S, Pan J, Tang Y, He S, Fu X, Peng X, Chen X, Yang C, Ren D, Huang Y, Liao Z, Huang S, Zou C,。 miR-204-5p Represses Bone Metastasis via Inactivating NF-κB Signaling in Prostate Cancer. Mol Ther Nucleic Acids. 2019 Dec 6;18:567-579. Epub 2019 Sep 18.
- Zou C#, Lin T#, Wang B, Zhao Z, Li B, Xie X, Huang G, Yin J, Shen J.Managements of giant cell tumor within the distal radius: A retrospective study of 58 cases from a single center.J Bone Oncol. 2018 Dec 14;14:100211. doi: 10.1016/j.jbo.2018.100211. eCollection 2019 Feb.
- Wang B, Zou C（共一）, Hu X, Tu J, Yao H, Yin J, Huang G, Xie X, Shen J. Reconstruction with a novel combined hemipelvic endoprosthesis after resection of periacetabular tumors involving the sacroiliac joint: a report of 25 consecutive cases.BMC Cancer. 2019 Aug 30;19(1):861.
- Shuai Huang, Changye Zou(共一), Yubo Tang, Qingde Wa, Xinsheng Peng, Xiao Chen, Chunxiao Yang, Dong Ren, Yan Huang, Zhuangwen Liao, Sheng Huang, Xuenong Zou, Jincheng Pan.miR-582-3p and miR-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF-β Signaling Mol Ther Nucleic Acids. 2019 Jun 7; 16: 91–104
- Liu W#, Zhang J#, Zou C#（共同第一作者）, Xie X, Wang Y, Wang B, Zhao Z, Tu J, Wang X, Li H, Shen J*, Yin J*. Miceoarray Expression Profile and Functional Analysis of Circular RNAs in Osteosarcoma, Cell Physiol Biochem, 2017;43(3):969-985.
- Wu J, Sun H1, Li J, Guo Y, Zhang K, Lang C, Zou C（共同通訊）, Ma H.Increased survival of patients aged 0-29 years with osteosarcoma: A period analysis, 1984-2013.Cancer Med. 2018 Jul 10. 2018 Aug;7(8):3652-3661
- Zou C#, Shen J#, Tang Q, Yang Z, Yin J, Li Z, Xie X, Huang G, Lev D, Wang J*,Cancer-testis antigens expression in osteosarcoma identified by gene microarray correlate with poor prognosis CANCER, 2012 Apr 1;118(7):1845-55
- Zou C#, Smith KD#, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE*, Lev D*， Clinical, pathological and molecular variables predictive of malignant peripheral nerve sheath tumor (MPNST) outcome Ann Surg. 2009 Jun;249(6):1014-22.
- Zou CY#, Smith KD#, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D*. Dual targeting of AKT and mTOR: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009 May;8(5):1157-68..
- Zou CY, Wang J, Shen JN*, Huang G, Jin S, Yin JQ, Guo QC, Li HM, Luo L, Zhang M, Zhang LJ. Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases Acta Pharmacol Sin. 2008 Mar;29(3):325-32
…….
專著：
無(wú)
其他主要工作成績(jī)（比如獲獎(jiǎng)情況）：
2012年作為青年骨干入選中山大學(xué)青年教師重點(diǎn)培育項(xiàng)目及中山大學(xué)附屬第一醫(yī)院優(yōu)秀青年人才支持計(jì)劃,，作為負(fù)責(zé)人承擔(dān)國(guó)家自然科學(xué)面上基金2項(xiàng),、省科技基金項(xiàng)目3項(xiàng)、高校專項(xiàng)基金項(xiàng)目3項(xiàng),。
